Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant enterovirus type 71 vaccine
- Development stage
- Unknown
- Lead developer
- Chongqing Bowei Baitai Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant enterovirus type 71 vaccine is a prophylactic biologic developed by Chongqing Bowei Baitai Biopharmaceutical for the prevention of hand, foot, and mouth disease (HFMD) caused by Enterovirus 71 (EV71) infection. Unlike traditional inactivated EV71 vaccines, this candidate utilizes a recombinant protein platform, specifically expressing virus-like particles (VLPs) or capsid proteins in the yeast *Hansenula polymorpha*. This expression system is designed to produce highly immunogenic antigens that mimic the structure of the native virus without containing live or inactivated viral genetic material. The vaccine is formulated with an aluminum-based adjuvant to enhance the induction of neutralizing antibodies. It aims to provide a scalable and safe alternative to whole-virus vaccines, targeting the primary genotypes responsible for HFMD outbreaks in the Asia-Pacific region.
- Other names
- recombinant enterovirus 71 vaccinerecombinant EV71 vaccinerecombinant enterovirus type 71 vaccine (Hansenula polymorpha)
Beyond the preview
Go deeper on recombinant enterovirus type 71 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant enterovirus type 71 vaccine.